search
Back to results

Honghuaruyi Wan for Endometriosis Dysmenorrhea

Primary Purpose

Endometriosis, Dysmenorrhea

Status
Not yet recruiting
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Honghuaruyi Wan
Placebo of Honghuaruyi Wan
Sponsored by
Beijing University of Chinese Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Endometriosis

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Meet the diagnostic criteria for endometriosis and have dysmenorrhea VAS score ≥4 points;
  2. Age 18 to 45;
  3. Regular menstrual cycle (28±7 days);
  4. Not pregnant at the time of seeing a doctor and no pregnancy plan during the medication, can insist on contraception;
  5. No pelvic nodules or adnexal masses, or pelvic nodules or adnexal masses ≤4cm;
  6. CA125 is normal or slightly elevated (below 200U/ml).
  7. Patients who voluntarily signed the informed consent and had conditional follow-up.

Exclusion Criteria:

  1. Patients who have known to have malignancies of reproductive organs or other malignancies;
  2. Suffering from serious diseases or mental diseases such as cardiovascular, cerebrovascular, liver, kidney or hematopoietic system;
  3. Uterine fibroids (≥3cm) and adenomyosis (uterine over 6 weeks of gestation, the reference value of uterine tridiameter at 6 weeks is 12cm, 7.5cm, 4.5cm);
  4. Those who received hormone drug therapy within 3 months before enrollment;
  5. lactating patients.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Honghuaruyi Wan

    Placebo

    Arm Description

    Honghuaruyi Wan will be used in this arm. Patients should start taking medicine with warm water on the first day of menstruation. For patients with VAS score < 7 points, 1g / time, twice a day; for patients with VAS score ≥ 7 points and pain is hard to bear, 2g / time, twice a day. According to the above usage and dosage, take 3 menstrual cycles continuously, and observe 3 menstrual cycles after stopping the drug.

    Placebo of Honghuaruyi Wan will be used in this arm. Patients should start taking medicine with warm water on the first day of menstruation. For patients with VAS score < 7 points, 1g / time, twice a day; for patients with VAS score ≥ 7 points and pain is hard to bear, 2g / time, twice a day. According to the above usage and dosage, take 3 menstrual cycles continuously, and observe 3 menstrual cycles after stopping the drug.

    Outcomes

    Primary Outcome Measures

    Visual Analogue Scale/Score (VAS)
    Draw a horizontal line of 10 cm on the paper. One end of the horizontal line is 0, indicating no pain.The other end is 10, which means severe pain; The part between the two ends represents different levels of pain. A higher score means a worse outcome.
    Endometriosis Health Profle-5(EHP-5)
    The core questionnaire contains 5 questions,every question has 5 answers:Never=0,Very few=1,Sometimes=2,Often=3,Always=4. The minimum and maximum values are between 0 to 20 and a higher value means a worse outcome.
    The 5-level EQ-5D version(EQ-5D-5L)
    There are 6 questions in the scale,the first 5 questions has 5 answers:No=0, A little bit=1, Moderate=2, Serious=3 Very serious=4. The minimum and maximum values are between 0 to 20 and a higher value means a worse outcome. The 6th question is about the status of the day visited. The minimum and maximum scores are between 0 to 100 and a higher value means a better outcome.

    Secondary Outcome Measures

    Visual Analogue Scale/Score (VAS) of the maximum non-menstrual pelvic pain
    Draw a horizontal line of 10 cm on the paper. One end of the horizontal line is 0, indicating no pain.The other end is 10, which means severe pain; The part between the two ends represents different levels of pain. A higher score means a worse outcome.
    The number of ibuprofen sustained-release capsules (or other NSAIDs) used
    The number of ibuprofen sustained-release capsules (or other NSAIDs) used
    Number of days off for staff/students due to dysmenorrhea
    Number of days off for staff/students due to dysmenorrhea
    The maximum diameter of the uterus
    The diameter of the uterus will be measured by B ultrasonic
    The maximum diameter of the cysts
    The diameter of the cysts will be measured by B ultrasonic

    Full Information

    First Posted
    May 27, 2021
    Last Updated
    June 18, 2021
    Sponsor
    Beijing University of Chinese Medicine
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04942015
    Brief Title
    Honghuaruyi Wan for Endometriosis Dysmenorrhea
    Official Title
    Beijing University of Chinese Medicine
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2021
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    June 21, 2021 (Anticipated)
    Primary Completion Date
    May 31, 2022 (Anticipated)
    Study Completion Date
    December 31, 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Beijing University of Chinese Medicine

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Endometriosis is a common gynecological disease. It is a gynecological disease caused by the growth and reproduction of the endometrium beyond the surface of the uterine tissue and organs, which causes recurrent abdominal pain, infertility and other main symptoms. The recurrence of endometriosis and the side effects of medication have troubled clinicians and patients for a long time and the search for new drugs is going on all the time. Honghuaruyi Wan is the traditional Tibetan prescription, clinical research has proved that Honghuaruyi Wan can significantly reduce risk mouse dysmenorrhea caused by oxytocin, improve dysmenorrhea model of mice body torsion times and improve the estrogen and progestogen operator Netherlands rat pituitary estradiol and prolactin level, at the same time also can reduce the amount of TNF alpha, thus improving endometriosis dysmenorrhea. In this study, the therapeutic effects of Honghuaruyi Wan provided by Tibet Qizheng Tibetan Medicine Co.,Ltd on secondary dysmenorrhea in patients with endometriosis was evaluated clinically. A multi-center, randomized, double-blind, placebo-controlled clinical trial was designed to provide evidence-based medical evidence for Honghuaruyi Wan in the treatment of endometriosis dysmenorrhea. In the design of this trial, the therapeutic effects and safety of Honghuaruyi Wan in the treatment of dysmenorrhea secondary to endometriosis were evaluated with Honghuaruyi Wan in the treatment group and placebo in the control group.
    Detailed Description
    Endometriosis (EM) is a common gynecological disease at present. It is a gynecological disease caused by the growth and reproduction of the endometrium on the surface of tissues and organs beyond the uterine covering surface, resulting in recurrent abdominal pain and infertility. The pathogenesis of endometriosis may be related to female endocrine dysfunction and abnormal levels of estrogen and progesterone in the body. Its clinical symptoms mainly include dysmenorrhea, chronic pelvic pain and sexual pain. The recurrence of endometriosis and the side effects of medication have troubled clinicians and patients for a long time. The search for new drugs has been going on. Honghuaruyi Wan is a traditional Tibetan prescription, which is made by addition and subtraction on the basis of the traditional and classic Tibetan medicine prescription "25 Wei Guijiu Wan". Its main ingredients are: Honghua,Xihonghua,Taoerqi,Kezi,Zangqiancao,Rougui,Baxiaga,Zangmuxiang,Yuansuiguo,Jiangxiang,Xiongdanfen,Zangzicao,Guangmingyan,Ximalayazimoli,Bangga,Hujiao,Huasherou,Aizijin,Yuganzi,Shajigao,Naosha,Zicaorong,Gouqizi,Chenxiang,Huoxiao. It has the effects of dispelling wind-evil and relieving pain, regulating menstrual blood and removing spots. It can be used for vaginitis, cervical erosion, irregular menstruation, dysmenorrhea and other common gynecological diseases. The main medicinal ingredients of Honghuaruyi Wan are Honghua ,Taoerqi and Zanghonghua, which have the effects of relieving pain, regulating menstruation and blood and dispersing knots. Some clinical studies have shown that the basic prescription of Honghuaruyi Wan have a significant effect on the improvement of dysmenorrhea, which can significantly reduce the incidence of dysmenorrhea caused by oxytocin in mice, and improve the number of body twisting in dysmenorrhea model mice. Other clinical studies have shown that Honghuaruyi Wan can improve estradiol and prolactin levels of pituitary gland in rats with estrogen and progesterone, as well as reduce TNF-α levels, thus improving endometriosis dysmenorrhea. For women of childbearing age who do not have fertility requirements, pain is the most important clinical symptom that needs to be addressed, especially with progressive dysmenorrhea. Therefore, in this study, the therapeutic effects of Honghuaruyi Wan, provided by Tibet Qizheng Tibetan Medicine Co.,Ltd, on the secondary dysmenorrhea of patients with endometriosis was evaluated clinically. A multi-center, randomized, double-blind, placebo-controlled clinical trial was designed to provide evidence-based medical evidence for Honghuaruyi Wan in the treatment of endometriosis dysmenorrhea. In the design of this trial, the therapeutic effects and safety of Honghuaruyi Wan in the treatment of dysmenorrhea secondary to endometriosis were evaluated with Honghuaruyi Wan in the treatment group and placebo in the control group.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Endometriosis, Dysmenorrhea

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    164 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Honghuaruyi Wan
    Arm Type
    Experimental
    Arm Description
    Honghuaruyi Wan will be used in this arm. Patients should start taking medicine with warm water on the first day of menstruation. For patients with VAS score < 7 points, 1g / time, twice a day; for patients with VAS score ≥ 7 points and pain is hard to bear, 2g / time, twice a day. According to the above usage and dosage, take 3 menstrual cycles continuously, and observe 3 menstrual cycles after stopping the drug.
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo of Honghuaruyi Wan will be used in this arm. Patients should start taking medicine with warm water on the first day of menstruation. For patients with VAS score < 7 points, 1g / time, twice a day; for patients with VAS score ≥ 7 points and pain is hard to bear, 2g / time, twice a day. According to the above usage and dosage, take 3 menstrual cycles continuously, and observe 3 menstrual cycles after stopping the drug.
    Intervention Type
    Drug
    Intervention Name(s)
    Honghuaruyi Wan
    Intervention Description
    Honghuaruyi Wan is the traditional Tibetan prescription, clinical research has proved that Honghuaruyi Wan can significantly reduce risk mouse dysmenorrhea caused by oxytocin, improve dysmenorrhea model of mice body torsion times and improve the estrogen and progestogen operator Netherlands rat pituitary estradiol and prolactin level, at the same time also can reduce the amount of TNF alpha, thus improving endometriosis dysmenorrhea.(Pill (15 pills/plate ×2 plates/box))
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo of Honghuaruyi Wan
    Intervention Description
    Honghuaruyi Wan simulation agent. Made of starch,dextrin and edible pigment from Tibet Qizheng Tibetan Medicine Co.,Ltd. ( Pill (15 pills/plate ×2 plates/box))
    Primary Outcome Measure Information:
    Title
    Visual Analogue Scale/Score (VAS)
    Description
    Draw a horizontal line of 10 cm on the paper. One end of the horizontal line is 0, indicating no pain.The other end is 10, which means severe pain; The part between the two ends represents different levels of pain. A higher score means a worse outcome.
    Time Frame
    Baseline through 6th consecutive menstrual cycle. (One cycle = 28±7days)
    Title
    Endometriosis Health Profle-5(EHP-5)
    Description
    The core questionnaire contains 5 questions,every question has 5 answers:Never=0,Very few=1,Sometimes=2,Often=3,Always=4. The minimum and maximum values are between 0 to 20 and a higher value means a worse outcome.
    Time Frame
    Baseline through 6th consecutive menstrual cycle. (One cycle = 28±7days)
    Title
    The 5-level EQ-5D version(EQ-5D-5L)
    Description
    There are 6 questions in the scale,the first 5 questions has 5 answers:No=0, A little bit=1, Moderate=2, Serious=3 Very serious=4. The minimum and maximum values are between 0 to 20 and a higher value means a worse outcome. The 6th question is about the status of the day visited. The minimum and maximum scores are between 0 to 100 and a higher value means a better outcome.
    Time Frame
    Baseline through 6th consecutive menstrual cycle. (One cycle = 28±7days)
    Secondary Outcome Measure Information:
    Title
    Visual Analogue Scale/Score (VAS) of the maximum non-menstrual pelvic pain
    Description
    Draw a horizontal line of 10 cm on the paper. One end of the horizontal line is 0, indicating no pain.The other end is 10, which means severe pain; The part between the two ends represents different levels of pain. A higher score means a worse outcome.
    Time Frame
    Baseline through 6th consecutive menstrual cycle. (One cycle = 28±7days)
    Title
    The number of ibuprofen sustained-release capsules (or other NSAIDs) used
    Description
    The number of ibuprofen sustained-release capsules (or other NSAIDs) used
    Time Frame
    Baseline through 6th consecutive menstrual cycle. (One cycle = 28±7days)
    Title
    Number of days off for staff/students due to dysmenorrhea
    Description
    Number of days off for staff/students due to dysmenorrhea
    Time Frame
    Baseline through 6th consecutive menstrual cycle. (One cycle = 28±7days)
    Title
    The maximum diameter of the uterus
    Description
    The diameter of the uterus will be measured by B ultrasonic
    Time Frame
    Baseline, After treatment (3rd menstrual cycle). (One cycle = 28±7days)
    Title
    The maximum diameter of the cysts
    Description
    The diameter of the cysts will be measured by B ultrasonic
    Time Frame
    Baseline, After treatment (3rd menstrual cycle). (One cycle = 28±7days)

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    45 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Meet the diagnostic criteria for endometriosis and have dysmenorrhea VAS score ≥4 points; Age 18 to 45; Regular menstrual cycle (28±7 days); Not pregnant at the time of seeing a doctor and no pregnancy plan during the medication, can insist on contraception; No pelvic nodules or adnexal masses, or pelvic nodules or adnexal masses ≤4cm; CA125 is normal or slightly elevated (below 200U/ml). Patients who voluntarily signed the informed consent and had conditional follow-up. Exclusion Criteria: Patients who have known to have malignancies of reproductive organs or other malignancies; Suffering from serious diseases or mental diseases such as cardiovascular, cerebrovascular, liver, kidney or hematopoietic system; Uterine fibroids (≥3cm) and adenomyosis (uterine over 6 weeks of gestation, the reference value of uterine tridiameter at 6 weeks is 12cm, 7.5cm, 4.5cm); Those who received hormone drug therapy within 3 months before enrollment; lactating patients.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Mei Han
    Phone
    +86 10 64287002
    Email
    hanmeizoujin@163.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Mei Han
    Organizational Affiliation
    Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicne
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    IPD Sharing Plan Description
    The data sharing plans for the current study are limited upon to contract with the company and might be made available upon agreement from the company.

    Learn more about this trial

    Honghuaruyi Wan for Endometriosis Dysmenorrhea

    We'll reach out to this number within 24 hrs